parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in tuft cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 4238

PTCHD1 in dopamine neurons, braak+0.00 (p 1.000) → +0.25 (p 0.514)receipt 4245
PTCHD1 in astrocytes, braak-0.37 (p 0.334) → +0.26 (p 0.498)receipt 4244

receipt 4245: PTCHD1 in dopamine neurons, braak

power: full sample +0.05 (p 0.847, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.03 (p 0.894, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.962, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.16, sign flips 4; without severely affected donors +0.05 (p 0.847, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PTCHD1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4244: PTCHD1 in astrocytes, braak

power: full sample -0.00 (p 0.990, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.01 (p 0.969, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.01 (p 0.983, n 18). could be the mix.
skeptic: leave-one-out range -0.11 to +0.13, sign flips 6; without severely affected donors -0.00 (p 0.990, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PTCHD1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts